Amedisys (AMED)
(Delayed Data from NSDQ)
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.12 USD
+0.08 (0.08%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $96.15 +0.03 (0.03%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth C Momentum A VGM
Zacks News
Henry Schein (HSIC) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Henry Schein (HSIC) is optimistic about maintaining robust sales of PPE and COVID-19-related products.
Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up
by Zacks Equity Research
Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.
Amedisys (AMED) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Growth in Home Health and Hospice along with recent innovation and acquisitions is expected to have contributed to Amedisys (AMED) top-line growth in Q1.
The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Addus HomeCare, LHC Group and Amedisys
Biden Chips in $400B for Home Healthcare: Stocks to Watch
by Sapna Bagaria
Biden's support to expand access to long-term care services under Medicaid bodes well for companies providing home healthcare.
Why Is Amedisys (AMED) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Amedisys (AMED) fourth-quarter 2020 revenues improve year over year, driven by strong growth across the Home Health and Hospice divisions.
Is a Surprise Coming for Amedisys (AMED) This Earnings Season?
by Zacks Equity Research
Amedisys (AMED) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Higher Business Volumes Aid Teladoc (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 earnings are likely to reflect higher visit volumes and subscriptions, along with an increase in marketing expenses.
Amedisys (AMED) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Amedisys (AMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Amedisys (AMED) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Amedisys (AMED) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Amedisys (AMED) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Amedisys (AMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Varian (VAR) Q1 Earnings Beat Estimates, Revenues Miss Mark
by Zacks Equity Research
Varian's (VAR) receipt of 13 Ethos orders in fiscal Q1 raises investors' optimism on the stock.
Encompass Health (EHC) Steadily Grows Inpatient Rehab Business
by Zacks Equity Research
Encompass Health (EHC) is continuously investing in post acute care services, which are in huge demand in the United States.
3 Biggest MedTech Trends to Watch in 2021 for Better Returns
by Sriparna Ghosal
Following are the three MedTech trends, which showed a steady momentum through the pandemic year and are likely to sustain even after the economic mayhem subsides.
Abbott (ABT) to Expand in Booming TBI Space on New Approval
by Zacks Equity Research
If positive, Abbott's (ABT) TBI blood test result complements CT scans to help evaluate whether a suspected patient has a TBI.
Phirbo (PAHC) Nutritional Specialty Aids Growth, Low ASP Ails
by Zacks Equity Research
Phirbo's (PAHC) net vaccine sales remain robust on higher international demand for poultry vaccines.
Hologic (HOLX) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Hologic's (HOLX) impressive preliminary results for the first quarter of fiscal 2021 and regulatory approvals.
Hologic (HOLX) Rides on Robust Preliminary Q1 Organic Sales
by Zacks Equity Research
The uptick in Hologic's (HOLX) Diagnostics sales is likely the result of increased demand for COVID-19 testing.
AngioDynamics (ANGO) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) witnesses revenue growth across two business segments in fiscal Q2.
Hologic (HOLX) to Expand in Oncology With Biotheranostics Buyout
by Zacks Equity Research
Hologic (HOLX) aims to strengthen its Diagnostics business by foraying into the oncology adjacency space via the acquisition of Biotheranostics.
Walgreens Boots (WBA) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Walgreens Boots' (WBA) fiscal first-quarter results reflect overall top-line improvement despite COVID-19-led business disruptions.
Zimmer Biomet (ZBH) Shows Strong APAC Recovery, EMEA Slow
by Zacks Equity Research
Zimmer Biomet (ZBH) is performing well in its priority areas like quality remediation, supply recovery efforts and product introductions.
Henry Schein (HSIC) Grows Inorganically, Closes JV, Buys Stake
by Zacks Equity Research
The developments are expected to strengthen Henry Schein's (HSIC) presence in high potential and still-untapped markets.
Hologic (HOLX) Completes SOMATEX Buyout, Expands Portfolio
by Zacks Equity Research
Hologic (HOLX) to expand biopsy portfolio as well as enhance patient experience via the SOMATEX buyout.